| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1047927356 |
| P356 | DOI | 10.1038/JID.2013.32 |
| P8608 | Fatcat ID | release_pfflpauegvakxlu2ae4net55la |
| P698 | PubMed publication ID | 23344460 |
| P5875 | ResearchGate publication ID | 235367090 |
| P2093 | author name string | Fang Liu | |
| Wenyi Wei | |||
| Byungwoo Ryu | |||
| James Shen | |||
| Rutao Cui | |||
| Zhixiang Xu | |||
| Jinxiang Wu | |||
| Juxiang Cao | |||
| Kayleigh Sullivan | |||
| P2860 | cites work | PAX3 gene structure and mutations: close analogies between Waardenburg syndrome and the Splotch mouse | Q48081349 |
| Oleic acid and linoleic acid are the major determinants of changes in keratinocyte plasma membrane viscosity. | Q52298793 | ||
| A genome-based strategy uncovers frequent BRAF mutations in melanoma. | Q53388101 | ||
| Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNalpha2b. | Q53568145 | ||
| A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. | Q55467677 | ||
| Effective elimination of fibroblasts in cultures of melanocytes by lowering calcium concentration in TPA depleted medium following geneticin treatment | Q71656592 | ||
| Validating Stat3 in cancer therapy | Q81816295 | ||
| Inhibition of PAX3 by TGF-beta modulates melanocyte viability | Q82695474 | ||
| The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner | Q21629049 | ||
| Splotch locus mouse mutants: models for neural tube defects and Waardenburg syndrome type I in humans | Q24514967 | ||
| Waardenburg syndrome | Q24517935 | ||
| Brachyury-related transcription factor Tbx2 and repression of the melanocyte-specific TRP-1 promoter. | Q24522646 | ||
| Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma | Q24597152 | ||
| Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation | Q24629474 | ||
| Improved survival with vemurafenib in melanoma with BRAF V600E mutation | Q24631953 | ||
| Concomitant tumor resistance: the role of tyrosine isomers in the mechanisms of metastases control | Q26865702 | ||
| Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling | Q27851628 | ||
| Inhibition of Mutated, Activated BRAF in Metastatic Melanoma | Q27860458 | ||
| Mutations of the BRAF gene in human cancer | Q27860760 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| Waardenburg's syndrome patients have mutations in the human homologue of the Pax-3 paired box gene | Q28181722 | ||
| Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma | Q29614282 | ||
| Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K | Q29614757 | ||
| COT drives resistance to RAF inhibition through MAP kinase pathway reactivation | Q29615032 | ||
| Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion | Q29617359 | ||
| Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. | Q33906093 | ||
| WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation | Q34745101 | ||
| STAT3: a multifaceted oncogene | Q34771828 | ||
| Tbx3 represses E-cadherin expression and enhances melanoma invasiveness. | Q34842421 | ||
| Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition | Q35146471 | ||
| Fibroblast growth factor receptor tyrosine kinases: molecular analysis and signal transduction | Q35229509 | ||
| Basic fibroblast growth factor and ultraviolet B transform melanocytes in human skin | Q35746395 | ||
| FGF2 regulates melanocytes viability through the STAT3-transactivated PAX3 transcription. | Q35840525 | ||
| The tumor microenvironment expression of p-STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models. | Q35871559 | ||
| Management of cutaneous melanoma | Q35877006 | ||
| The expression of p-STAT3 in stage IV melanoma: risk of CNS metastasis and survival | Q35987091 | ||
| A mutation within intron 3 of the Pax-3 gene produces aberrantly spliced mRNA transcripts in the splotch (Sp) mouse mutant | Q36059319 | ||
| STAT3 mediates resistance to MEK inhibitor through microRNA miR-17. | Q36083385 | ||
| Melanocyte stem cell maintenance and hair graying | Q36093772 | ||
| Targeting STAT3 affects melanoma on multiple fronts | Q36178382 | ||
| Targeting intracellular signaling pathways as a novel strategy in melanoma therapeutics | Q36355180 | ||
| Malignant melanoma: genetics and therapeutics in the genomic era. | Q36567158 | ||
| Toward a molecular classification of melanoma. | Q36795253 | ||
| A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells | Q36973832 | ||
| A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells | Q37172697 | ||
| BRAF, a target in melanoma: implications for solid tumor drug development | Q37772444 | ||
| Mutant BRAF melanomas--dependence and resistance | Q37830845 | ||
| Analysis of radiation-induced changes to human melanoma cultures using a mathematical model | Q39707030 | ||
| Braf(V600E) cooperates with Pten loss to induce metastatic melanoma | Q39873596 | ||
| PAX3 expression in primary melanomas and nevi | Q40004728 | ||
| UV-mediated regulation of the anti-senescence factor Tbx2. | Q40048508 | ||
| Amino acid residues required for physical and cooperative transcriptional interaction of STAT3 and AP-1 proteins c-Jun and c-Fos | Q40106192 | ||
| Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells | Q40972355 | ||
| STAT3 mediates the survival signal in oncogenic ras-transfected intestinal epithelial cells | Q41003470 | ||
| ERK and PI3K negatively regulate STAT-transcriptional activities in human melanoma cells: implications towards sensitization to apoptosis. | Q42443548 | ||
| Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma | Q43665317 | ||
| Paracrine stimulation of melanocytes by keratinocytes through basic fibroblast growth factor | Q43874334 | ||
| Pax3 transcripts in melanoblast development | Q46826614 | ||
| WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells | Q46868533 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2041-2049 | |
| P577 | publication date | 2013-01-23 | |
| P1433 | published in | Journal of Investigative Dermatology | Q3186921 |
| P1476 | title | Stat3-targeted therapies overcome the acquired resistance to vemurafenib in melanomas | |
| P478 | volume | 133 |
| Q38757495 | A Nexus Consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to Vemurafenib |
| Q43088864 | A STATement on vemurafenib-resistant melanoma. |
| Q64250277 | Advances in the Understanding of Skin Cancer: Ultraviolet Radiation, Mutations, and Antisense Oligonucleotides as Anticancer Drugs |
| Q35251663 | BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth |
| Q35154624 | Breast cancer cells condition lymphatic endothelial cells within pre-metastatic niches to promote metastasis |
| Q94476206 | Cellular plasticity and metastasis in breast cancer: a pre- and post-malignant problem |
| Q92577646 | Danazol mediates collateral sensitivity via STAT3/Myc related pathway in multidrug-resistant cancer cells |
| Q33861173 | Development, characterization, and reversal of acquired resistance to the MEK1 inhibitor selumetinib (AZD6244) in an in vivo model of childhood astrocytoma |
| Q36377576 | Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation. |
| Q97424535 | Dual Inhibition of MAPK and JAK2/STAT3 Pathways Is Critical for the Treatment of BRAF Mutant Melanoma |
| Q36951681 | FOXD3 Promotes PAX3 Expression in Melanoma Cells |
| Q36115818 | Fibroblast-derived neuregulin 1 promotes compensatory ErbB3 receptor signaling in mutant BRAF melanoma |
| Q64273467 | Identification of a Novel Quinoxaline-Isoselenourea Targeting the STAT3 Pathway as a Potential Melanoma Therapeutic |
| Q41075854 | Improvement of cancer immunotherapy by combining molecular targeted therapy. |
| Q38142161 | MITF and PAX3 Play Distinct Roles in Melanoma Cell Migration; Outline of a "Genetic Switch" Theory Involving MITF and PAX3 in Proliferative and Invasive Phenotypes of Melanoma |
| Q35187734 | MITF in melanoma: mechanisms behind its expression and activity. |
| Q38143977 | Melanoma biomolecules: independently identified but functionally intertwined. |
| Q38821729 | Microfluidic co-cultures with hydrogel-based ligand trap to study paracrine signals giving rise to cancer drug resistance |
| Q50897128 | Modulating cancer cell survival by targeting intracellular cholesterol transport. |
| Q26795735 | Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets |
| Q35225907 | Nanolipolee-007, a novel nanoparticle-based drug containing leelamine for the treatment of melanoma. |
| Q38724921 | Nanoparticle-Based Celecoxib and Plumbagin for the Synergistic Treatment of Melanoma. |
| Q36528249 | Nifuroxazide exerts potent anti-tumor and anti-metastasis activity in melanoma |
| Q36562077 | Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma |
| Q35768281 | PAX3 and ETS1 synergistically activate MET expression in melanoma cells |
| Q64971077 | PAX3 is a biomarker and prognostic factor in melanoma: Database mining. |
| Q37688157 | PIM kinases as therapeutic targets against advanced melanoma |
| Q35320304 | Phosphoproteomic analysis of basal and therapy-induced adaptive signaling networks in BRAF and NRAS mutant melanoma |
| Q64083402 | Role of STAT3 dependent SOX2 and CD24 expression in melanoma cell adaptive resistance towards targeted therapies |
| Q92447468 | STAT3 Relays a Differential Response to Melanoma-Associated NRAS Mutations |
| Q90383577 | STAT3 and STAT5 Targeting for Simultaneous Management of Melanoma and Autoimmune Diseases |
| Q60921447 | STAT3 enhances the constitutive activity of AGC kinases in melanoma by transactivating PDK1 |
| Q38787620 | Suppression of B-Raf(V600E) cancers by MAPK hyper-activation |
| Q59797793 | Targeted Therapy-Resistant Melanoma Cells Acquire Transcriptomic Similarities with Human Melanoblasts |
| Q92646241 | Targeting STAT3 restores BRAF inhibitor sensitivity through miR-759-3p in human cutaneous melanoma cells |
| Q38110540 | Targeting Tregs in Malignant Brain Cancer: Overcoming IDO. |
| Q53835262 | Targeting melanoma with NT157 by blocking Stat3 and IGF1R signaling. |
| Q47139368 | The anti-apoptotic BAG3 protein is involved in BRAF inhibitor resistance in melanoma cells |
| Q39388206 | The potential for targeting the STAT3 pathway as a novel therapy for melanoma |
| Q38543552 | The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours. |
| Q48090844 | Transcription factors as critical players in melanoma invasiveness, drug resistance, and opportunities for therapeutic drug development. |
| Q42320717 | Usp9x regulates Ets-1 ubiquitination and stability to control NRAS expression and tumorigenicity in melanoma. |
| Q65000687 | [What’s new in dermato-oncology?]. |
Search more.